Hon CHRIS HIPKINS: Without knowing the details of exactly what the requirement for isolation is and what the risk profile of that is, it would be unwise to venture an opinion on that. In terms of the use of rapid antigen tests, yes, I think we will see a much wider use of rapid antigen tests, particularly for surveillance testing, and where businesses are able to—